A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

About

Brief Summary

Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene.

The purpose of this study is to:

Learn about the safety of DB-OTO
Determine how well DB-OTO is tolerated (does not cause ongoing discomfort)
Evaluate the efficacy of DB-OTO (how well DB-OTO works)

Primary Purpose

Treatment

Study Type

Interventional

Phase

Phase 1/Phase 2

Eligibility

Gender

All

Healthy Volunteers

No

Minimum Age

N/A

Maximum Age

17 Years

Inclusion Criteria:

Presence of pathogenic or likely pathogenic mutations in both alleles of the OTOF gene.
Patient is <18 years of age and of the appropriate age to qualify for enrollment in the corresponding age cohort at the time the parent/legal guardian signs the informed consent form. Participant to provide assent, when applicable
Audiological Criteria: US:
- Investigator determines that minimal benefit has been provided by amplification of the ear to receive DB-OTO.
- Investigator determines the patient meets cochlear implantation criteria in both ears according to the recommended cochlear implant label Infants ≤24 months of age:
- Profound sensorineural hearing loss (SNHL; ≥ 90 dB HL) based on behavioral and physiologic measurements (ABR) of inner ear function.
- Outer hair cell function is confirmed by presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO Children >24 months to <18 years of age:
- Profound SNHL (≥ 90 dB HL) based on physiologic measurements (ABR) of inner ear function AND
- Behavioral open-set word recognition scores of < 30% in the ear that would receive DB-OTO
- Outer hair cell function is confirmed by presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO OR
- Presence of a cochlear microphonic in ears to receive DB-OTO. UK & Spain: Infants ≤24 months of age:
- Absence of an ABR neural signal in response to a click stimulus ≤85 dB nHL in the ear(s) to be injected with DB-OTO.
- Presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO. Children >24 months to <18 years of age:
- Absence of an ABR neural signal in response to a click stimulus ≤85 dB nHL in the ear(s) to be injected with DB-OTO.
- Presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO OR
- Presence of a cochlear microphonic in ears to receive DB-OTO.
Willingness of at least 1 parent/legal guardian to consent to vaccinations for the patient in accordance with the country-specific pediatric immunization schedule
No clinically significant laboratory findings on clinical laboratory tests at time of Screening
No evidence that hearing loss is dependent on body temperature
From study start and for the duration of the short-term follow-up period (18 months): Female patients of childbearing potential and fertile males, must agree to use highly effective contraception. Female patients must agree not to become pregnant. Fertile male patients must agree not to father a child or donate sperm.

Exclusion Criteria:

History or presence of other permanent or untreatable hearing loss conditions.
Prior or current cochlear implants in the ear(s) to be injected with DB-OTO
History of risk factor(s) for auditory neuropathy not caused by OTOF mutations including: prematurity, low birth weight, hyperbilirubinemia, neonatal intensive care unit (NICU) admission, and/or low Apgar scores.
Prior or current history of malignancies.
Prior or current history of meningitis.
History of prior treatment with gene therapy.
Surgical anatomy that would preclude the planned surgical approach as indicated by medical imaging (eg, computed tomography [CT] or magnetic resonance imaging [MRI]) in the ear(s) to be injected with DB-OTO.